Avalo Therapeutics, Inc.

NASDAQ:AVTX

Biotechnology

Healthcare
$6.70 -2.18%

-$0.34 today

Market cap
$387.41M
Beta
0.82
P/E (TTM)
-3.6
EPS (TTM)
-$4.21
52W Low $4.50High $24.27

Volume 1.58M

Average 1.61M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$51.46M

FY 2025 · Annual

Investing Cash Flow

-$81.72M

FY 2025 · Annual

Financing Cash Flow

$14.59M

FY 2025 · Annual

-91.7% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(84.38M)(41.66M)(31.54M)(35.13M)(78.26M)
Depreciation & Amortization1.66M166K158K169K344K
Deferred Income Tax22K28K14K114K165K
Stock-Based Compensation8.17M7.55M3.48M5.85M13.62M
Change in Working Capital2.84M(60K)(9.24M)(4.71M)3.84M
Accounts Receivables1.12M2.88M1.78M(475K)0
Inventory(35K)18K20K00
Accounts Payables796K(487K)(2.44M)(163K)(146K)
Other Working Capital961K(2.47M)(8.61M)(4.07M)3.99M
Other Non-Cash Items794K7.22M6.46M(15.35M)8.83M
Operating Cash Flow(70.89M)(26.75M)(30.68M)(49.06M)(51.46M)
Capital Expenditures(113K)(95K)(158K)00
Acquisitions (Net)000356K0
Purchases of Investments0000(113.72M)
Sales of Investments000031.31M
Other Investing Activities0025K0690K
Investing Cash Flow(113K)(95K)(133K)356K(81.72M)
Debt Repayment32.9M(14.81M)(21.24M)00
Common Stock Issued71.93M107K46.22M115.63M15.1M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.93M067K60.22M(510K)
Financing Cash Flow106.76M(14.7M)25.04M175.85M14.59M
Effect of Forex Changes096K000
Net Change in Cash35.76M(41.45M)(5.77M)127.15M(118.59M)
Free Cash Flow(71.01M)(26.85M)(30.84M)(49.06M)(51.46M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$78.3M
+ D&A$344.0K
+ Stock-Based Comp$13.6M
+ Deferred Tax$165.0K
+ Working Capital$3.8M
+ Other Non-Cash$8.8M
= Operating Cash Flow-$51.5M
- Capex$0
= Free Cash Flow-$51.5M

Analysis

FY2025 free cash flow is -$51.5M. FCF conversion is 65.8% of net income. Operating cash flow was -$51.5M, with capex of $0. The largest bridge item is Stock-Based Comp at $13.6M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 13, 2026
SC 13GSC 13G filingNov 10, 2026
SC 13G/ASC 13G/A filingNov 6, 2026
S-3ASRS-3ASR filingNov 5, 2026
SC 13G/ASC 13G/A filingNov 5, 2026

Does AVTX generate free cash flow?

Avalo Therapeutics, Inc. (AVTX) generated -$51.46M of free cash flow in fiscal 2025.

How much operating cash flow does AVTX produce?

Operating cash flow was -$51.46M, before capital expenditures of $0.00.